Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Paarl, South Africa Clinical Trials

A listing of Paarl, South Africa clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02

This study will evaluate the safety and efficacy of Relamorelin compared to placebo in patients with diabetic gastroparesis. Patients will report daily severity scores of their diabetic gastroparesis symptoms.

Phase

0.0 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials will have the option to enroll in this trial to receive study medication for up to 5 years or until marketed approval

Phase

1.84 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent Adult and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

This double-blind (neither researchers nor participants know what treatment participant is receiving) study will evaluate efficacy/safety of pimodivir in combination with SOC treatment versus placebo in combination with SOC treatment in adolescent (13 to 17 years), adult (18 to 65 years), and elderly (greater than [>] 65 but less than ...

Phase

1.84 miles

Learn More »

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

The primary objective of this study is to test the hypothesis that glycemic control, as measured by change in hemoglobin A1c (HbA1c) from baseline to endpoint, with exenatide is superior to that of placebo after 28 weeks of treatment in adolescent patients with type 2 diabetes who are nave to ...

Phase

4.13 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 Followed by PNEUMOVAX 23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018/PNEU-WAY)

This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in pneumococcal vaccine-nave adults infected with HIV and to 2) describe the safety, tolerability, and immunogenicity of PNEUMOVAX23 when administered 8 weeks after receipt of either V114 or Prevnar 13.

Phase

4.13 miles

Learn More »